ASCO 2021: Presentations about whole genome sequencing
At the congress of the American Society of Clinical Oncology (ASCO) on 4-8 June 2021 researchers Kris Samsom and Luuk Schipper of the Dutch Cancer Institute (NKI) have presented their findings on whole genome sequencing.
In the poster presentation
Whole Genome Sequencing (WGS) is feasible in routine clinical care
Kris Samsom of the Dutch Cancer Institute explains the results of their research in which they conclude that WGS is feasible in routine diagnostics.
In the poster presentation
Whole Genome Sequencing (WGS) improves sarcoma diagnosis and patient care
Luuk Schipper of the Dutch Cancer Institute explains how they came to the conclusion in their research that WGS can help improve the diagnosis and the treatment of patients with sarcomas.
More information
- Paper in The Journal of Molecular Diagnostics: Clinical validation of Whole Genome Sequencing for cancer diagnostics
- Interview with Kim Monkhorst, patholoog NKI/AvL about the interim results of WIDE: Whole Genome Sequencing feasible in clinical practice
- More information about WGS and the extensive DNA test: OncoAct.nl
All news
Also read
Take a virtual tour of our laboratory: from the biopsy to the patient report
What happens to your tumor tissue and blood during a comprehensive DNA test? What exactly does all the complex equipment …
Unique insights in the differences between primary and metastatic cancer by large-scale DNA data analyses
Researchers have obtained valuable insights into the development of tumors from a unique Dutch data collection. These insights provide relevant …
New cancer treatment options created by full DNA-analysis
Nature publication reports study by Netherlands Center for Personalized Cancer Treatment showing benefits for targeted treatments outside registered indications 2 …
The fact that the CPCT, together with Hartwig Medical Foundation, has managed to bundle data, knowledge and expertise from almost all Dutch hospitals is unique and now also deserves international attention.